Clinical Trials Logo

Cerebral Vein Thrombosis clinical trials

View clinical trials related to Cerebral Vein Thrombosis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05448248 Completed - Clinical trials for Cerebral Venous Sinus Thrombosis

Multicenter Registry Study Of Cerebral Venous Thrombosis In China (RETAIN-CH)

Start date: August 20, 2022
Phase:
Study type: Observational

This study will investigate the epidemiology, risk factors, diagnostics, treatment, and the long-term prognosis of cerebral venous thrombosis in China.

NCT ID: NCT04569279 Completed - Clinical trials for Cerebral Vein Thrombosis

Rivaroxaban vs. Warfarin in CVT Treatment

RWCVT
Start date: September 1, 2017
Phase: Phase 3
Study type: Interventional

Cerebral venous thrombosis (CVT) is an uncommon venous-type of stroke tends to affect younger patients with somewhat different risk factors and much better outcome compared to arterial strokes. Anti-coagulation is the standard of treatment for patients with (CVT) initially with heparins followed by other oral blood thinners for several months. In this study, the investigators are comparing warfarin with another well-known blood thinner, rivaroxaban, which has a fixed once-daily dose with no need for monitoring in terms of clinical outcomes and complications.

NCT ID: NCT02585713 Completed - Pulmonary Embolism Clinical Trials

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Start date: November 20, 2015
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies the side effects of and compares apixaban and dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism. Venous thromboembolism is a condition in which a blood clot forms in a vein and then breaks off and moves through the bloodstream. Patients with cancer are at increased risk for venous thromboembolism. Apixaban and dalteparin are drugs used to prevent blood clots from forming or to treat blood clots that have formed. It is not yet known whether apixaban or dalteparin is more effective in reducing blood clots in patients with cancer related venous thromboembolism. ADAM-VTE